Issue Date: July 25, 2016
Celgene invests big in Jounce
Celgene will pay $225 million up front and make a $36 million equity investment to collaborate with Jounce Therapeutics, a three-year-old company focused on cancer immunotherapies and predictive biomarkers. In return, Celgene will have options on Jounce’s lead product candidate, JTX-2011, and up to four early-stage programs. Expected to soon enter clinical trials, JTX-2011 is an antibody that activates a T-cell surface protein believed to stimulate an anticancer immune response. Jounce could earn up to $2.3 billion in milestone payments across all the programs.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society